MAPK8 and myeloid leukemia: Prolonged activation of JNK and p38 MAPKs was previously reported in human myelogenous leukemia cells treated with Shiga toxin type 1, while modest and transient activation of ERK 1/2 was reported (Leyva-Illades et al., 2010).